Compare Citius Pharmaceuticals Inc (CTXR) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Nuscale Power Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Nuscale Power Corporation trades at $7.16 (market cap $3.00B). The key difference: Nuscale Power Corporation is far larger — about 220.3× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 43,143,109). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Nuscale Power Corporation for 29 Days on average.
| CTXR | SMR | |
|---|---|---|
Market Cap | $13.62M | $3.00B |
Volume | 132,438 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $1.82 | $53.43 |
52-Week Low | $0.48 | $7.32 |
Typical Hold Time | 17 Days | 29 Days |
Enterprise Value | $3.79M | $1.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
SMR trades at $7.145, down 6.84% on the day, reflecting ongoing investor concerns. The stock is technically bearish with moving averages signaling a downtrend, while fundamentals show severe losses with a net income margin of -3,888.7% in 2026 and negative cash flow from operations. Recent news highlights a Pomerantz law firm investigation into the company, adding to headwinds despite some analyst optimism.
The outlook remains high-risk; while 50% of analysts rate it a buy with a $11.25 consensus target, persistent losses, cash burn, and competitive pressures in the nuclear SMR space pose significant challenges. Upside depends on successful commercialization, but current financials and sentiment suggest caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
